JP2012509892A - サティオゲン類を含有する組成物及び使用の方法 - Google Patents

サティオゲン類を含有する組成物及び使用の方法 Download PDF

Info

Publication number
JP2012509892A
JP2012509892A JP2011537692A JP2011537692A JP2012509892A JP 2012509892 A JP2012509892 A JP 2012509892A JP 2011537692 A JP2011537692 A JP 2011537692A JP 2011537692 A JP2011537692 A JP 2011537692A JP 2012509892 A JP2012509892 A JP 2012509892A
Authority
JP
Japan
Prior art keywords
peptide
secretagogue
certain embodiments
bile
rectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509892A5 (https=
Inventor
エー． ヤング，アンドリュー
ゲドリン，ブロニスラヴァ
グリーン，ハワード，イー．
Original Assignee
サティオゲン ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サティオゲン ファーマシューティカルズ，インク． filed Critical サティオゲン ファーマシューティカルズ，インク．
Publication of JP2012509892A publication Critical patent/JP2012509892A/ja
Publication of JP2012509892A5 publication Critical patent/JP2012509892A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011537692A 2008-11-26 2009-11-23 サティオゲン類を含有する組成物及び使用の方法 Pending JP2012509892A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11832408P 2008-11-26 2008-11-26
US61/118,324 2008-11-26
US25521109P 2009-10-27 2009-10-27
US61/255,211 2009-10-27
PCT/US2009/065587 WO2010062863A2 (en) 2008-11-26 2009-11-23 Compositions containing satiogens and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014004971A Division JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Publications (2)

Publication Number Publication Date
JP2012509892A true JP2012509892A (ja) 2012-04-26
JP2012509892A5 JP2012509892A5 (https=) 2013-01-17

Family

ID=41572705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011537692A Pending JP2012509892A (ja) 2008-11-26 2009-11-23 サティオゲン類を含有する組成物及び使用の方法
JP2014004971A Pending JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014004971A Pending JP2014062134A (ja) 2008-11-26 2014-01-15 サティオゲン類を含有する組成物

Country Status (7)

Country Link
US (3) US8318663B2 (https=)
EP (1) EP2364161B1 (https=)
JP (2) JP2012509892A (https=)
CN (1) CN102316889B (https=)
CA (1) CA2744697C (https=)
GB (1) GB2465677B (https=)
WO (1) WO2010062863A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
WO2017170854A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 有効成分の化学的安定性に優れたフィルムコーティング錠
JP2022544239A (ja) * 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
KR20110120866A (ko) * 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
WO2012151252A2 (en) * 2011-05-02 2012-11-08 Biokier, Inc. Composition and method for treatment of diabetes
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9301938B2 (en) 2009-09-23 2016-04-05 Biokier, Inc. Composition and method for treatment of diabetes
EP2485738A4 (en) * 2009-10-09 2015-04-01 Atheronova Operations Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS
WO2011075539A2 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of obesity or diabetes with bile acid sequestrants
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
EP2739286A4 (en) * 2011-08-04 2015-06-03 Lumena Pharmaceuticals Inc GALLENIC ACID FLUID FOR THE TREATMENT OF PANCREATITIS
WO2013049595A1 (en) * 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US9402968B2 (en) 2012-07-11 2016-08-02 Mercy Medical Research Institute, Inc. Colorectal delivery device
CN104644591A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种沙格列汀药物组合物及其制备方法
KR101812530B1 (ko) * 2014-02-12 2017-12-27 야마하하쓰도키 가부시키가이샤 촬영 장치, 차량 및 화상 보정 방법
JP7164950B2 (ja) * 2014-10-31 2022-11-02 ユニバーシティー オブ ユタ リサーチ ファウンデーション 胆汁酸粒子の組成物及び方法
EP3115037B1 (de) * 2015-07-08 2018-08-15 Dr. Falk Pharma Gmbh Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
EP3890745B1 (en) 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
JP2020186223A (ja) * 2019-05-09 2020-11-19 救心製薬株式会社 牛黄及び／又は鹿茸及び／又は胆汁酸を含有する組成物
KR20250171471A (ko) 2019-05-10 2025-12-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 장 박테리아 담즙산 대사의 소분자 조정제
CN110314167A (zh) * 2019-07-04 2019-10-11 北京大学第三医院（北京大学第三临床医学院） 胆汁酸作为制备治疗pcos药物的应用及药物制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6396138A (ja) * 1986-10-07 1988-04-27 エフ・ホフマン―ラ　ロシユ　アーゲー 製薬学的組成物
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
KR970005178B1 (ko) 1993-12-28 1997-04-14 이승철 피로회복제 조성물
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
EP2583675A1 (en) * 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
JP2000026300A (ja) 1998-07-02 2000-01-25 Pola Chem Ind Inc 血管内皮細胞保護医薬組成物
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1743655B1 (en) * 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CA2401290A1 (en) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
US7198914B2 (en) 2000-11-17 2007-04-03 Banyu Pharmaceutical Co., Ltd. Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
MXPA04011584A (es) * 2002-05-23 2005-03-31 Umd Inc Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
US7312208B2 (en) * 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JP2005097216A (ja) * 2003-09-26 2005-04-14 Kaneka Corp ＰＰＡＲγリガンド剤
EP1819318A1 (en) 2004-11-24 2007-08-22 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation
US20060193895A1 (en) * 2005-02-25 2006-08-31 Use-Techno Corporation Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
FR2883284A1 (fr) 2005-03-15 2006-09-22 Commissariat Energie Atomique Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
US20080031968A1 (en) * 2005-04-01 2008-02-07 The Brigham And Women's Hospital, Inc. Methods for increasing cellular energy expenditure
WO2006116814A1 (en) 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
DE502007006208D1 (de) 2006-11-14 2011-02-17 Sanofi Aventis Deutschland Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US20080221161A1 (en) * 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
KR20110120866A (ko) 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US9301938B2 (en) 2009-09-23 2016-04-05 Biokier, Inc. Composition and method for treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6396138A (ja) * 1986-10-07 1988-04-27 エフ・ホフマン―ラ　ロシユ　アーゲー 製薬学的組成物
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6013002670; 渡辺光博: Ｆｕｎｃｔｉｏｎａｌ　Ｆｏｏｄ Ｖｏｌ．２，　Ｎｏ．１, 200804, ｐ．５７-６３ *
JPN6013002673; ＨＯＳＮＹ，　Ｅ．Ａ．　ｅｔ　ａｌ．: Ｄｒｕｇ　Ｄｅｖｅｌｏｐｍｅｎｔ　ａｎｄ　Ｉｎｄｕｓｔｒｉａｌ　Ｐｈａｒｍａｃｙ Ｖｏｌ．２７，　Ｎｏ．８, 2001, ｐ．８３７-８４５ *
JPN6013002675; ＫＡＴＳＵＭＡ，　Ｓ．　ｅｔ　ａｌ．: Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．３２９, 2005, ｐ．３８６-３９０ *
JPN6013002677; ＤＵＭＯＵＬＩＮ，　Ｖ．　ｅｔ　ａｌ．: Ｅｎｄｏｃｒｉｎｏｌｏｇｙ Ｖｏｌ．１３９，　Ｎｏ．９, 1998, ｐ．３７８０-３７８６ *
JPN6013002680; ＡＤＲＩＡＮ，　Ｔ．Ｅ．　ｅｔ　ａｌ．: Ｇｕｔ． Ｖｏｌ．３４, 1993, ｐ．１２１９-１２２４ *
JPN6013002682; ＲＥＩＭＡＮＮ，　Ｆ．　ｅｔ　ａｌ．: ＤＩＡＢＥＴＥＳ Ｖｏｌ．５５，　Ｓｕｐｐｌ．２, 2006, Ｓ７８-Ｓ８５ *
JPN6013002684; 難波光義ら: 日本消化器学会雑誌 Ｖｏｌ．１０２，　Ｎｏ．１１, 2005, ｐ．１３９８-１４０４ *
JPN6013002686; ＢＡＬＡＳ，　Ｂ．　ｅｔ　ａｌ．: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｅｎｄｏｃｒｉｎｏｌｏｇｙ　＆　Ｍｅｔａｂｏｌｉｓｍ Ｖｏｌ．９２，　Ｎｏ．４, 2007, ｐ．１２４９-１２５５ *
JPN6013002687; ＲＡＵＮ，　Ｋ．　ｅｔ　ａｌ．: ＤＩＡＢＥＴＥＳ Ｖｏｌ．５６, 2007, ｐ．８-１５ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
WO2017170854A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 有効成分の化学的安定性に優れたフィルムコーティング錠
JPWO2017170854A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 有効成分の化学的安定性に優れたフィルムコーティング錠
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
JP2022544239A (ja) * 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法

Also Published As

Publication number Publication date
CA2744697C (en) 2016-06-21
EP2364161A4 (en) 2012-12-26
US9345715B2 (en) 2016-05-24
GB0920703D0 (en) 2010-01-13
CN102316889B (zh) 2014-11-26
EP2364161A2 (en) 2011-09-14
CN102316889A (zh) 2012-01-11
US10028952B2 (en) 2018-07-24
WO2010062863A3 (en) 2010-09-23
JP2014062134A (ja) 2014-04-10
CA2744697A1 (en) 2010-06-03
US20160235745A1 (en) 2016-08-18
WO2010062863A2 (en) 2010-06-03
US20100130426A1 (en) 2010-05-27
US20130190281A1 (en) 2013-07-25
GB2465677B (en) 2012-09-26
EP2364161B1 (en) 2020-03-11
US8318663B2 (en) 2012-11-27
GB2465677A (en) 2010-06-02

Similar Documents

Publication Publication Date Title
US10028952B2 (en) Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
US20220362238A1 (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20130034536A1 (en) Bile Acid Recycling Inhibitors for Treatment of Pancreatitis
US20110152204A1 (en) Treatment of Obesity or Diabetes with Bile Acid Sequestrants
US20110311621A1 (en) Pharmaceutical compositions and methods of delvery
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
HK40088265A (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20240100001A1 (en) Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
US20250032590A1 (en) Parathyroid hormone compounds in the treatment of hypoparathyroidism
US9198879B2 (en) Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA)
HK40021032A (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN118055778A (zh) 苦味受体激动剂和肠信号传导化合物的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121121

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121220

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130917